Prime Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PRME$3.90-9.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity F-
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders' Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount | ||||||
| Balances at December 31, 2023 | 97,377,121 | $2 | $624,414 | $(15) | $(491,330) | $133,071 |
| Issuance of common stock from public offering, net of issuance costs of $8.9 million | 22,560,001 | — | 132,055 | — | — | 132,055 |
| Issuance of pre-funded warrants, net of issuance costs of $1.2 million | — | — | 18,800 | — | — | 18,800 |
| Issuance of common stock under the Securities Purchase Agreement to BMS — related party (Note 9) | 11,006,163 | — | 38,081 | — | — | 38,081 |
| Issuances of common stock under the employee stock purchase plan | 189,509 | — | 837 | — | — | 837 |
| Issuances of common stock upon exercise of stock options | 28,048 | — | 103 | — | — | 103 |
| Stock-based compensation expense | — | — | 26,068 | — | — | 26,068 |
| Change in unrealized loss on investments, net of tax | — | — | — | 16 | — | 16 |
| Net loss | — | — | — | — | (195,882) | (195,882) |
| Balances at December 31, 2024 | 131,160,842 | $2 | $840,358 | $1 | $(687,212) | $153,149 |
| Issuance of common stock from public offering, net of issuance costs of $5.8 million | 43,700,000 | — | 138,390 | — | — | 138,390 |
| Issuance of restricted stock units | 2,000,000 | — | — | — | — | — |
| Exercise of pre-funded warrants | 3,199,984 | — | — | — | — | — |
| Issuance of common stock under the employee stock purchase plan | 231,166 | — | 341 | — | — | 341 |
| Issuance of common stock upon exercise of stock options | 222,022 | — | 781 | — | — | 781 |
| Stock-based compensation expense | — | — | 29,268 | — | — | 29,268 |
| Change in unrealized loss on investments, net of tax | — | — | — | 81 | — | 81 |
| Net loss | — | — | — | — | (201,142) | (201,142) |
| Balances at December 31, 2025 | 180,514,014 | $2 | $1,009,138 | $82 | $(888,354) | $120,868 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.